Faculty of Medicine, Physiology Department, Mardin Artuklu University, Mardin, Turkey.
Faculty of Medicine, Emergency Department, Mardin Artuklu University, Mardin, Turkey.
Medicine (Baltimore). 2024 Apr 5;103(14):e37743. doi: 10.1097/MD.0000000000037743.
Increased serum chemerin levels have been reported in several inflammatory diseases. Few studies have investigated the relationship between chemerin and clinical features of COVID-19. Thus, chemerin may modulate the development and progression of COVID-19. We compared the serum chemerin concentration between patients with and without SARS-CoV-2 infection and its association with the severity and prognosis of COVID-19 pneumonia. This is a prospective, single-center, cross-sectional study. We enrolled COVID-19 patients who presented to our tertiary hospital and healthy controls. The COVID-19 patients were conducted and the dates of symptom onset were recorded. After admission to the hospital and stabilization, blood samples were obtained for routine hemogram, biochemistry, and chemerin. The chemerin level was 37.93 ± 17.3 ng/mL in patients followed in the ICU, 29.41 ± 12.79 ng/mL in inpatients, 30.48 ± 10.86 ng/mL in outpatients, and 25.12 ± 9.82 ng/mL in healthy controls. The difference between patients treated in the ICU and healthy controls was significant (P < .001). The high-sensitivity C-reactive protein (hs-CRP), ferritin, procalcitonin (PCT), and D-dimer levels were significantly higher in the intensive care unit (ICU) group (P < .001). Moreover, the chemerin level of patients who died was significantly higher than that of those who survived (P < .001). The chemerin level was increased in COVID-19 patients and also increased with increasing disease severity. The chemerin level was higher in the COVID-19 patients than healthy controls and was significantly higher in patients who died compared to those who did not.
在几种炎症性疾病中，已报道血清趋化素水平升高。少数研究调查了趋化素与 COVID-19 的临床特征之间的关系。因此，趋化素可能调节 COVID-19 的发生和进展。我们比较了 SARS-CoV-2 感染患者和未感染患者的血清趋化素浓度及其与 COVID-19 肺炎严重程度和预后的关系。这是一项前瞻性、单中心、横断面研究。我们招募了就诊于我们三级医院的 COVID-19 患者和健康对照者。记录 COVID-19 患者的就诊日期和症状出现日期。入院并稳定后，采集血样进行常规血常规、生化和趋化素检查。入住 ICU 的患者的趋化素水平为 37.93±17.3ng/mL，住院患者为 29.41±12.79ng/mL，门诊患者为 30.48±10.86ng/mL，健康对照者为 25.12±9.82ng/mL。入住 ICU 的患者与健康对照者之间的差异有统计学意义（P<0.001）。重症监护病房（ICU）组高敏 C 反应蛋白（hs-CRP）、铁蛋白、降钙素原（PCT）和 D-二聚体水平明显升高（P<0.001）。此外，死亡患者的趋化素水平明显高于存活患者（P<0.001）。COVID-19 患者的趋化素水平升高，且随疾病严重程度增加而增加。COVID-19 患者的趋化素水平高于健康对照者，死亡患者明显高于未死亡患者。
